EUVIMEDEUVIMED entdecken
Crossref

ZYX knockdown alleviates chemotherapy resistance in epithelial ovarian cancer

Xiangyun Hu, Shijiao Wang, Ruihui Yang, Xiaoting Zhang, Yaoyao He, Changtao Zheng, Ying Ding, Huainian Zhang, Ali Chen, Yongxia Yang, Yongli Zhang

Biochemical Pharmacology · 2026-12 · 254 · 118570

DOI: 10.1016/j.bcp.2026.118570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-12. Verfasst von Xiangyun Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006,…. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Science and Technology Planning Project of Shenzhen Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high mortality of epithelial ovarian cancer (EOC) is largely attributable to chemotherapy resistance. This study identifies Zyxin (ZYX) as a key driver of this resistance. ZYX was overexpressed in chemoresistant EOC patients and corresponding paclitaxel-resistant (A2780/PTX) and cisplatin-resistant (A2780/DDP) cell lines. Functional experiments demonstrated that ZYX knockdown reversed chemoresistance by suppressing proliferation and migration, inducing apoptosis, and causing cell cycle arrest. Mechanistically, ZYX promotes resistance by interacting with Glycogen synthase kinase 3 beta (GSK3B), while its knockdown enhances paclitaxel sensitivity via β-tubulin upregulation and inhibits migration by reducing microfilament formation. Furthermore, ZYX knockdown potentiated paclitaxel efficacy in chemosensitive SKOV3 cells, both in vitro and in vivo. Our findings establish ZYX as a promising therapeutic target for overcoming chemotherapy resistance in EOC.

Schlagwörter

Stichwörter der Autor:innen

Chemotherapy resistanceEpithelial ovarian cancerZyxinsmall interfering RNA

Autor:innen und Institutionen

  • Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, PR China.
  • Central Laboratory, Shenzhen Bao'an District Songgang People's Hospital, Shenzhen, Guangdong, 518100, PR China.
  • Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510062, PR China.
  • Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, PR China.
  • Center for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, PR China. Electronic address: chenali@gd…
  • School of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510006, PR China. Electronic address: yangyongxia@gdpu.edu.cn.

Förderung

  • Science and Technology Planning Project of Shenzhen Municipality

Zitieren

APA

Hu, X., Wang, S., Yang, R., Zhang, X., He, Y., Zheng, C., Ding, Y., Zhang, H., Chen, A., Yang, Y., & Zhang, Y. (2026). ZYX knockdown alleviates chemotherapy resistance in epithelial ovarian cancer. Biochemical Pharmacology, 254, 118570. https://doi.org/10.1016/j.bcp.2026.118570

Vancouver

Hu X, Wang S, Yang R, Zhang X, He Y, Zheng C, et al. ZYX knockdown alleviates chemotherapy resistance in epithelial ovarian cancer. Biochemical Pharmacology. 2026;254:118570. doi:10.1016/j.bcp.2026.118570

BibTeX
@article{Hu2026,
  author = {Hu, Xiangyun and Wang, Shijiao and Yang, Ruihui and Zhang, Xiaoting and He, Yaoyao and Zheng, Changtao and Ding, Ying and Zhang, Huainian and Chen, Ali and Yang, Yongxia and Zhang, Yongli},
  title = {ZYX knockdown alleviates chemotherapy resistance in epithelial ovarian cancer},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {254},
  pages = {118570},
  doi = {10.1016/j.bcp.2026.118570}
}
Kostenlos starten →